LYON, France, June 5 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, intends to add the University of Colorado Health Sciences Center at Denver, to its US study participating sites. Dr. E. David Crawford, M.D., Professor and Head of Urologic Oncology will lead the study program.

"HIFU represents one of the most exciting advances in local prostate cancer treatment in the past decade," said Dr. David Crawford, Head of Urologic Oncology. "We are honored to be a part of the US clinical study for the approval of HIFU. Our center is known for its clinical focus on developing better therapeutic options. After a careful review of all HIFU options for prostate cancer, Ablatherm-HIFU is the clear choice with a proven clinical record at large global centers, low side effects for the patient and excellent science backing its proven treatment protocols. We look forward to participating in the study with our patients."

As a national and international lecturer on detection methods, treatment options, and treatment outcomes of prostate cancer, Dr. Crawford has authored or coauthored more than 450 articles published in medical journals. He also serves on the editorial boards of Oncology, Primary Care & Cancer, and the Journal of Cellular Biochemistry and edited 5 textbooks on urologic oncology. He has received two Freddie Awards for best medical videos and has been on a number of television programs, including Good Morning America, Today, and NBC Nightly News. He is one of the co-founders of Prostate Cancer Awareness Week (PCAW), which provides free or low cost prostate cancer screenings for men across the US every September. Dr. Crawford is a fellow of the American College of Surgeons, and an active member of the American Urological Association, the American Society of Clinical Oncology, and the Southwest Oncology Group (SWOG). He serves on the advisory boards of Us Too, the Prostate Health Council, and the Prostate Cancer Trialists Collaborative Group.

Dr. David Crawford is also the organizer of the renowned annual International Prostate Cancer Update Conference, which gathers the leading international opinion leaders in prostate cancer to review and discuss the existing therapies and promising new options offered to patients with prostate cancer. The recent conference in February 2007 at Vail, CO, including growing interest in HIFU based on Ablatherm's clinical record.

The Ablatherm-HIFU Phases II/III clinical study is currently enrolling men diagnosed with clinical stage T1a, b or c or T2a localized prostate cancer. HIFU is a noninvasive therapy using highly focused ultrasound energy to ablate the prostate tissue. Details of the study and background on Ablatherm-HIFU can be found online at http://www.clinicaltrials.gov by searching for "Ablatherm." Ablatherm-HIFU is proven effective comparable to other standard nonsurgical treatments of localized prostate cancer, but often offers fewer side effects.

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.

To sign up for alerts please visit http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A. Magnolia Investor Relations

                Blandine Confort      Matt Kreps
                +33 4 78 26 40 46     972 801 4900

SOURCE EDAP TMS S.A.